Acasti Pharma, Inc. - (ACST) News

Acasti Pharma, Inc. - (ACST): $0.59

-0.02 (-3.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ACST News Items

ACST News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACST News Highlights

  • ACST's 30 day story count now stands at 4.
  • Over the past 9 days, the trend for ACST's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ACST are DRUG, RARE and GTX.

Latest ACST News From Around the Web

Below are the latest news stories about ACASTI PHARMA INC that investors may wish to consider to help them evaluate ACST as an investment opportunity.

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, joined Stock Day host Everett Jolly. Jolly began the interview by commenting on a recent press release detailing the Company's clinical study for its GTX-102 asset, an oral mucosal spray targeting Ataxia-telang

Yahoo | September 21, 2022

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

LAVAL, Québec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022. Company Webcast The Company’s webcast presentation will be available for viewing at 9:00am ET on Wed

Yahoo | September 14, 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, GTX-102, compared to an intramuscular injection of betamethasone and to an oral solution of betamethasone, in 48 healthy subjects. The First Subject, First Dose was administered on S

Yahoo | September 13, 2022

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced that management will virtually participate at the H.C. Wainwright 24th Annual Global Investment Conference September 12-16, 2022. The webcasted presentation will be available on demand at the H.C. Wainwright Conference Platform for

Yahoo | September 12, 2022

Edited Transcript of ACST.V earnings conference call or presentation 11-Aug-22 5:00pm GMT

Q1 2023 Acasti Pharma Inc Earnings Call

Yahoo | August 11, 2022

Acasti Pharma Reports First Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ETLAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced financial and operational results for the first quarter ended June 30, 2022. Recent Highlights The Company is preparing the GTX-104 PK bridging study results for submission to the U.S

Yahoo | August 11, 2022

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Thursday, August 11, 2022, to discuss the Company’s corporate progress and other developments, as well as financial results for first quarter 2023 ended June 30, 2022. The conference call will be available via telephone by diali

Yahoo | August 2, 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed drug bupivacaine in 48 healthy subjects. Feedback from FDA was obtained on the study protocol, and the non-objection letter was received on July 12th from Health Canada. The First-Subject, First-Dose was a

Yahoo | July 27, 2022

Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - July 7, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and novel drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, joined Stock Day host Sever Copley. Copley began the interview by asking about one of the Company's lead clinical assets, GTX-104, targeting underserved orphan diseases. D'Alvise elaborated that GTX-104 is a ..

Yahoo | July 7, 2022

Acasti Pharma Announces Annual Grants of Performance Stock Options

LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced the annual grant of performance stock options to its employees and executives. An aggregate of 1,212,500 stock options were granted to certain employees and executives of the Company under the Company’s stock option plan (“Stock Opti

Yahoo | June 22, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6302 seconds.